An older adult with chronic hepatitis C, possible intravenous drug use, and currently taking bupropion, fluoxetine, venlafaxine extended‑release, zolpidem, clonazepam, and lamotrigine, who may have undiagnosed dementia, what is the most appropriate next step in management?

Management of Possible Undiagnosed Dementia in an Older Adult with Chronic Hepatitis C and Complex Polypharmacy

Immediate Priority: Formal Cognitive Assessment and Medication Deprescribing

The most appropriate next step is to perform formal cognitive assessment using the Montreal Cognitive Assessment (MoCA) or Saint Louis University Mental Status (SLUMS) examination while simultaneously initiating systematic deprescribing of the current psychotropic polypharmacy, which is likely contributing to or causing the cognitive impairment. 1

This patient's medication regimen—bupropion, fluoxetine, venlafaxine extended-release, zolpidem, clonazepam, and lamotrigine—represents dangerous polypharmacy that is almost certainly worsening or even causing the suspected dementia. 2, 3

---

Step 1: Establish Whether True Dementia Exists or If This Is Drug-Induced Cognitive Impairment

Perform Structured Cognitive Testing

• Use the MoCA, SLUMS, or Rowland Universal Dementia Assessment Scale (RUDAS) to quantify baseline cognitive function and establish objective documentation of impairment severity. 1
• Screen specifically for depression using validated instruments, as depression frequently mimics or coexists with dementia in elderly patients and may be driving the polypharmacy. 1

Critical Differential Diagnosis Considerations

• Drug-induced dementia occurs in over 10% of patients attending memory clinics and is potentially reversible with medication withdrawal. 3
• Long-acting benzodiazepines (clonazepam) are the most common drugs to cause or exacerbate dementia in elderly patients. 2
• The combination of multiple psychotropic agents dramatically increases the risk of cognitive impairment beyond any single agent. 2
• Hepatitis C infection independently increases dementia risk (adjusted HR 1.36,95% CI 1.27-1.42), meaning this patient has both medication-induced and disease-related cognitive vulnerability. 4

Rule Out Hepatic Encephalopathy

• Measure plasma ammonia level—a normal value essentially rules out hepatic encephalopathy as the cause of cognitive impairment. 5
• Check for signs of liver decompensation: ascites, asterixis, jaundice, and review liver function tests and platelet count. 5
• Hepatic encephalopathy must be distinguished from dementia, as the treatments and prognoses differ fundamentally. 5

---

Step 2: Systematic Medication Deprescribing (Begin Immediately)

Highest Priority: Discontinue Clonazepam

• Benzodiazepines are the most common cause of drug-induced dementia and must be tapered immediately. 2, 3
• Taper clonazepam gradually over 2–4 weeks to avoid withdrawal symptoms, including rebound insomnia and anxiety. 6
• Benzodiazepines cause tolerance, addiction, cognitive impairment, increased delirium risk, and paradoxical agitation in approximately 10% of elderly patients. 6, 2

Second Priority: Rationalize the Triple Antidepressant Regimen

• The combination of fluoxetine, bupropion, and venlafaxine represents irrational polypharmacy without evidence of synergistic benefit and dramatically increases anticholinergic burden and cognitive impairment risk. 2, 3
• Fluoxetine should be avoided in older adults due to its very long half-life, extensive CYP2D6 interactions, higher rates of adverse effects, and greater risk of agitation. 7, 8
• Consolidate to a single first-line agent: either sertraline (starting 25–50 mg daily) or escitalopram (starting 10 mg daily), both of which have the best evidence for safety and tolerability in older adults. 8
• Allow 4–8 weeks at optimized dosing for full therapeutic assessment before concluding treatment failure. 8

Third Priority: Discontinue Zolpidem

• Zolpidem increases fall risk, cognitive impairment, and delirium in elderly patients. 6
• Implement non-pharmacological sleep hygiene interventions: ensure adequate lighting, reduce excessive noise, establish predictable bedtime routines, increase daytime bright light exposure (2 hours of morning bright light at 3,000–5,000 lux), and reduce time in bed during the day. 6

Fourth Priority: Review Lamotrigine Indication and Hepatotoxicity Risk

• Lamotrigine can cause severe hepatotoxicity, particularly in patients with underlying liver disease such as chronic hepatitis C. 9
• If lamotrigine was prescribed for mood stabilization in the context of bipolar disorder, reassess whether the diagnosis is accurate or whether the patient's symptoms represent treatment-resistant depression exacerbated by polypharmacy. 6
• Monitor hepatic function closely if lamotrigine is continued, especially given the hepatitis C diagnosis. 9

---

Step 3: Investigate Reversible Medical Causes of Cognitive Impairment

Laboratory Evaluation

• Vitamin B12 and folate levels: deficiency causes reversible dementia. 1
• Thyroid-stimulating hormone (TSH): hypothyroidism mimics dementia. 1
• Complete blood count and comprehensive metabolic panel: rule out anemia, electrolyte disturbances (especially hyponatremia from SSRIs), renal dysfunction, and hepatic decompensation. 1
• Serum sodium: SSRIs cause clinically significant hyponatremia in 0.5–12% of elderly patients, typically within the first month of treatment. 8

Brain Imaging

• Obtain non-contrast MRI of the brain (or non-contrast CT if MRI is contraindicated) to rule out structural causes: subdural hematoma, stroke, normal pressure hydrocephalus, or space-occupying lesions. 5, 1

Assess for Infection and Metabolic Disturbances

• Screen for urinary tract infection, pneumonia, and other infections that disproportionately cause cognitive impairment in elderly patients. 5, 6
• Check for constipation, urinary retention, dehydration, and pain—all of which worsen confusion in patients who cannot verbally communicate discomfort. 5, 6

---

Step 4: Determine Whether Dementia Diagnosis Is Accurate After Deprescribing

Reassess Cognitive Function After Medication Withdrawal

• Repeat formal cognitive testing (MoCA or SLUMS) 4–6 weeks after completing medication deprescribing to determine whether cognitive impairment persists. 1
• If cognitive function improves substantially, the diagnosis was drug-induced cognitive impairment, not true dementia. 2, 3
• If cognitive impairment persists despite medication rationalization and treatment of reversible causes, proceed with dementia workup and consider referral to neurology. 1

Differentiate Dementia from Mild Cognitive Impairment (MCI)

• MCI is an intermediate state between normal aging and dementia, with preserved daily functioning despite cognitive deficits. 5
• Covert hepatic encephalopathy and MCI show significant symptom overlap, but hepatic encephalopathy causes severe functional impairment and fluctuating symptoms, whereas MCI symptoms are stable over at least 6 months. 5

---

Step 5: If True Dementia Is Confirmed, Initiate Appropriate Management

Pharmacological Treatment for Dementia

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide symptomatic benefit when initiated during the dementia stage and maintained through late clinical stages. 5
• Combination therapy (cholinesterase inhibitor plus memantine) provides cumulative, additive benefits over monotherapy in moderate-to-severe dementia. 5
• These medications do not alter the underlying disease process but mitigate clinical decline. 5

Non-Pharmacological Interventions

• Implement lifestyle modifications: smoking cessation, regular exercise, optimized nutrition, and social engagement to slow cognitive decline. 5
• Provide caregiver education and connect with support agencies such as the Alzheimer's Association. 5
• Enroll in safety programs such as "Safe Return" and consider assistive technologies (GPS pendants, medication dispensers, in-home cameras). 5

---

Critical Pitfalls to Avoid

• Do not add antipsychotics or additional psychotropics before completing deprescribing and reassessing cognitive function. Adding more medications will worsen cognitive impairment and increase mortality risk. 6, 2
• Do not assume dementia is irreversible without first withdrawing potentially offending medications. Over 10% of suspected dementia cases are iatrogenic and reversible. 3
• Do not continue benzodiazepines indefinitely. Clonazepam is the single most likely medication causing or exacerbating this patient's cognitive impairment. 2, 3
• Do not use fluoxetine in older adults. It has a very long half-life, extensive drug interactions, and higher rates of adverse effects compared to sertraline or escitalopram. 7, 8
• Do not overlook hepatic encephalopathy. Measure ammonia level and assess for liver decompensation, as hepatitis C patients are at risk for both hepatic encephalopathy and dementia. 5, 4

---

Summary Algorithm

1. Perform formal cognitive testing (MoCA or SLUMS) to quantify baseline impairment. 1
2. Measure plasma ammonia to rule out hepatic encephalopathy. 5
3. Begin immediate deprescribing: taper clonazepam over 2–4 weeks, discontinue zolpidem, consolidate to single antidepressant (sertraline or escitalopram), and reassess lamotrigine indication. 6, 8, 2, 3
4. Rule out reversible causes: check B12, folate, TSH, sodium, CBC, CMP, and obtain brain MRI. 1
5. Reassess cognitive function 4–6 weeks after deprescribing to determine whether impairment was drug-induced or represents true dementia. 2, 1, 3
6. If dementia persists, initiate cholinesterase inhibitor and implement non-pharmacological interventions. 5